Medulloblastoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Medulloblastoma – Pipeline Review, H1 2017’, provides an overview of the Medulloblastoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Medulloblastoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Medulloblastoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Medulloblastoma

The report reviews pipeline therapeutics for Medulloblastoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Medulloblastoma therapeutics and enlists all their major and minor projects

The report assesses Medulloblastoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Medulloblastoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Medulloblastoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Medulloblastoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Bayer AG

Bristol-Myers Squibb Company

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Lipocure Ltd

MacroGenics Inc

NewLink Genetics Corp

Novogen Ltd

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Medulloblastoma - Overview

Medulloblastoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Medulloblastoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Medulloblastoma - Companies Involved in Therapeutics Development

Bayer AG

Bristol-Myers Squibb Company

DelMar Pharmaceuticals Inc

Ignyta Inc

IMPACT Therapeutics Inc

Lipocure Ltd

MacroGenics Inc

NewLink Genetics Corp

Novogen Ltd

Ono Pharmaceutical Co Ltd

Progenics Pharmaceuticals Inc

Stemline Therapeutics Inc

ThromboGenics NV

VBI Vaccines Inc

Medulloblastoma - Drug Profiles

(topotecan hydrochloride + vincristine sulfate) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Target IL13Ralpha2 and CD3 for Melanoma, Glioblastoma Multiforme and Medulloblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bispecific Monoclonal Antibodies to Target ROR1 and CD3 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dianhydrogalactitol - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Edotreotide Labeled Yttrium 90 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMP-5471 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

indoximod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

irinotecan hydrochloride + TBio-02 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-5 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nifurtimox SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nivolumab - Drug Profile

R&D Progress

Oncolytic Virus to Target CD46 and SLC5A5 for Brain Tumor and Recurrent Medulloblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

p28 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pyrvinium pamoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit STAT3 for Medulloblastoma and Glioblastoma Multiforme - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

taladegib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

THR-317 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Trilexium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VBI-1901 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIMO-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMY-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Medulloblastoma - Dormant Projects

Medulloblastoma - Product Development Milestones

Featured News & Press Releases

Nov 10, 2016: VBI Vaccines to Present at the Society of Neuro-Oncology Annual Meeting

Oct 13, 2016: DelMar Pharmaceuticals Announces Upcoming Scientific Conference Presentations

Oct 05, 2016: VBI Vaccines to Present at the World Vaccine Congress Europe

Aug 29, 2016: VBI Vaccines to Present at the Immuno-Oncology Summit

Jun 16, 2016: VBI Vaccines Announces Medulloblastoma Immunotherapy Program

Mar 15, 2016: FDA Grants Second Orphan Designation For VAL-083

Feb 19, 2016: Novogen Patent Covering Trilexium Has Been Proceeded To Grant

Nov 11, 2015: DelMar Pharmaceuticals Presents Data Supporting VAL-083 as a Promising Potential Treatment for Pediatric Brain Tumors

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Medulloblastoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Medulloblastoma – Pipeline by Bayer AG, H1 2017

Medulloblastoma – Pipeline by Bristol-Myers Squibb Company, H1 2017

Medulloblastoma – Pipeline by DelMar Pharmaceuticals Inc, H1 2017

Medulloblastoma – Pipeline by Ignyta Inc, H1 2017

Medulloblastoma – Pipeline by IMPACT Therapeutics Inc, H1 2017

Medulloblastoma – Pipeline by Lipocure Ltd, H1 2017

Medulloblastoma – Pipeline by MacroGenics Inc, H1 2017

Medulloblastoma – Pipeline by NewLink Genetics Corp, H1 2017

Medulloblastoma – Pipeline by Novogen Ltd, H1 2017

Medulloblastoma – Pipeline by Ono Pharmaceutical Co Ltd, H1 2017

Medulloblastoma – Pipeline by Progenics Pharmaceuticals Inc, H1 2017

Medulloblastoma – Pipeline by Stemline Therapeutics Inc, H1 2017

Medulloblastoma – Pipeline by ThromboGenics NV, H1 2017

Medulloblastoma – Pipeline by VBI Vaccines Inc, H1 2017

Medulloblastoma – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Medulloblastoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports